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1,3,5-TriazineAbstract As a part of our quest for the synthesis of new bioactive heterocyclic compounds, in our
present work we have synthesized a series of 4-(4-(arylamino)-6-(piperidin-1-yl)-1,3,5-triazine-2-y-
lamino)-N-(pyrimidin-2-yl)benzenesulfonamide (3a–o) derivatives. The newly synthesized com-
pounds were screened for their in vitro antimicrobial activity. Compounds 3c, 3n and 3o
exhibited signiﬁcant antimicrobial activity on several strains of microbes. The structures of newly
synthesized compounds were elucidated by IR, 1H NMR, 13C NMR and Mass spectral analysis.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Globally, researchers are trying to synthesize new drugs with
better pharmacokinetic and pharmacodynamic properties with
fewer adverse effects. In the recent decades due to rapid devel-
opment in drug resistance, tolerance and side effects, there is a
need for the evolution of a new generation of antimicrobialagents that exhibit improved pharmacological properties and
drug-resistance proﬁle. Recently, a number of clinical reports
indicated that the multi-drug resistant microorganisms have
reached an alarming level in many countries around the globe.
Infections caused by these microorganisms pose a serious chal-
lenge to the medical community and the need for an effective
therapy has led to the search for novel antimicrobial agents
[1–3]. In this aspect, substituted s-triazine, sulfonamide and
piperidine derivatives have received attention due to their sig-
niﬁcant antimicrobial [4], antibacterial [5], antifungal [6], anti-
HIV [7], anticancer [8], anti-tubercular [9], antitumor [10], anti-
inﬂammatory [11] and other biological activities [12,13].
1,3,5-Triazines represent a widely used lead structure with
interesting applications in numerous ﬁelds [14,15]. Several
speciﬁc synthetic protocols were developed for the preparation
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2,4,6-trichloro-1,3,5-triazine i.e. cyanuric chloride is an impor-
tant, inexpensive starting material due to higher reactivity
toward nucleophiles [17,18]. Piperidine moiety is a very impor-
tant pharmacophore because of its presence in numerous alka-
loids, pharmaceuticals and diverse applications in medicinal
area [19]. This heterocyclic moiety is found in drugs like parox-
etine, risperidone, methylphenidate, raloxifene, minoxidil and
thioridazine. Biologically active alkaloids containing substitut-
ed piperidine ring systems have been targeted by medicinal
chemists, for their complete or partial synthesis [20]. Sulfon-
amides having the –NH–SO2– group are known to exhibit a
broad range of biological activities such as antimicrobial
[21], antimalarial, antileprotic [22], diuretic, hypoglycemic
and anti-thyroid [23].
Our research group previously reported synthesis, charac-
terization and antimicrobial evaluation of N’-(4-(arylamino)-
6-(thiazol-2-ylamino)-1,3,5-triazin-2-yl)isonicotinohydrazide
derivatives [24] and 4-(4-(2-isonicotinoylhydrazinyl)-6-((aryl)a-
mino)-1,3,5-triazin-2-ylamino)-N-(pyrimidin-2-yl) benzenesul-
fonamides [25]. In continuation to this, to design novel
antimicrobial agents, we developed a new hypothesis to incor-
porate benzenesulfonamide, piperidine and s-triazine scaffolds
in one framework.2. Experimental part
2.1. Materials and physical measurements
The completion of reaction and purity of compounds were
checked on aluminum coated TLC plates 60 F245 (E. Merck)
using n-hexane: ethyl acetate (7.5: 2.5 V/V) as mobile phase
and visualized under ultraviolet (UV) light or in an iodine cham-
ber.Melting points were determined on an electro thermal melt-
ing point apparatus and were reported uncorrected. Elemental
analysis (% C, H, N) was carried out by a Perkin-Elmer 2400
CHN analyzer. IR spectra of all the compounds were recorded
on a Perkin-Elmer FT-IR spectrophotometer using KBr. 1H
NMR (400 MHz) and 13C NMR (100 MHz) spectra were
recorded on a Bruker spectrometer using DMSO-d6 as solvent
and TMS as an internal standard. Mass spectra were obtained
on a SHIMADZU LC–MS 2010 spectrometer.
2.2. Chemistry
The chlorine atoms of 2,4,6-trichloro-s-triazine exhibit tem-
perature dependent reactivity in the presence of NaOH
(hydrochloride acceptor). There is stepwise nucleophilic dis-
placement of three chlorine atoms by various aromatic amines.
This leads to the synthesis of trisubstituted 1,3,5-triazines
according to the reported procedure [26].
2.2.1. 4-(4,6-Dichloro-1,3,5-triazin-2-ylamino)-N-(pyrimidin-2-
yl)benezenesulfonamide(1)
In the ﬁrst step, nucleophilic substitution reaction on cyanuric
chloride in acetone with 4-amino-N-(pyrimidin-2-yl)benzene-
sulfonamide at 0–5 C temperature in the presence of 4%
NaOH, provided vital and efﬁcient intermediate (1) by neutral-
ization of reaction mixture with dil. HCl i.e. 4-(4,6-dichloro-1,3,5-triazine-2-ylamino)-N-(pyrimidin-2-yl)benezenesulfonamide.
Yield 80%; m.p.180–185 C. IR (mmax, cm1, KBr): 3342 (N–
H, 2 amine), 2980 (C–H, aromatic), 1626 (C‚N), 1569
(C‚C), 1285 (C–N), 1170 (S‚O). 1H NMR (400 MHz,
DMSO-d6, d, ppm): 6.54 (s, 1H, Ar–NH–triazine), 6.89 (t,
1H, C5-H pyrimidine ring), 7.25–7.62 (m, 6H, Ar–H), 8.17
(s, 1H, –NH–SO2–), 8.86 (d, 2H, C4-H & C6-H pyrimidine
ring). 13C NMR (100 MHz, DMSO-d6, d, ppm): 115.2 (1C,
C2 pyrimidine ring), 129.5 (1C, aromatic C–SO2NH–), 142.0
(1C, SO2-aromatic C–NH–), 157.6 (2C, C4 & C6 pyrimidine
ring), 169.2 (1C, C2 pyrimidine ring), 169.9 (2C, C4-Cl & C6-Cl
triazine ring), 170.8 (1C, C2 triazine ring). LC–MS (m/z):
396.99 [M+]. Anal. Calcd. for C13H9Cl2N7O2S: C, 39.21; H,
2.28; N, 24.62; Found: C, 39.20; H, 2.25; N, 24.60%.2.2.2. 4-(4-Chloro-6-(piperidin-1-yl)-1,3,5-triazin-2-ylamino)-
N-(pyrimidin-2yl)benzenesulfonamide (2)
Subsequently reaction of 4-(4,6-dichloro-1,3,5-triazine-2-y-
lamino)-N-(pyrimidin-2-yl)benezenesulfonamide with piperi-
dine at room temperature in the presence of 4% NaOH,
followed by neutralization with dil. HCl yielded intermediate
(2) i.e. 4-(4-chloro-6-(piperidin-1-yl)-1,3,5-triazine-2-ylamino)-
N-(pyrimidin-2-yl) benzenesulfonamide. Yield 78%; m.p.
232–235 C. IR (mmax, cm1, KBr): 3342 (N–H, 2 amine),
2980 (C–H, aromatic), 1626 (C‚N), 1569 (C‚C), 1285 (C–
N), 1170 (S‚O). 1H NMR (400 MHz, DMSO-d6, d, ppm):
1.54–3.68 (m, 10H, piperidine), 6.58 (s, 1H, Ar–NH–triazine),
6.87 (t, 1H, pyrimidine), 6.93–7.62 (m, 6H, Ar–H), 8.13 (s, 1H,
pyrimidine–NH–SO2–), 8.84 (d, 2H, pyrimidine). 13C NMR
(100 MHz, DMSO-d6, d, ppm): 24.1 (1C, C4 piperidine), 25.2
(2C, C3 & C5 piperidine ring), 54.2 (2C, C2 & C6 piperidine
ring), 129.5 (1C, aromatic C–SO2NH–), 142.0 (1C, –SO2-aro-
matic C–NH–), 157.6 (2C, C4 & C6 pyrimidine ring), 169.1
(1C, C2 pyrimidine ring), 169.7 (1C, C2 triazine ring), 177.0
(1C, C6-Cl triazine ring), 177.7 (1C, C6 triazine ring). LC–
MS (m/z):446.10 [M+]. Anal. Calcd. for C18H19ClN8O2S: C,
48.37; H, 4.29; N, 25.07; Found: C, 48.35; H, 4.28; N, 25.05%.2.2.3. Preparation of 4-(4-(aryl)amino)-6-(piperidin-1-yl)-
1,3,5-triazine-2-ylamino)-N-(pyrimidin-2-
yl)benzenesulfonamides (3a–o)
Synthesis of 4-(4-(aryl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-
ylamino)-N-(pyrimidin-2-yl)benzenesulfonamides was accom-
plished in three steps. The reaction sequence employed for the
synthesis of targeted compounds (3a–o) is illustrated in
Scheme 1. In the ﬁrst step, nucleophilic substitution reaction
on cyanuric chloride in acetone with 4-amino-N-(pyrimidin-2-
yl)benzenesulfonamide at 0–5 C temperature in the presence
of 4% NaOH, provided vital and efﬁcient intermediate (1) i.e.
4-(4,6-dichloro-1,3,5-triazine-2-ylamino)-N-(pyrimidin-2-yl)
benezenesulfonamide. Subsequently, it was reacted with piperi-
dine at room temperature to yield intermediate (2) i.e. 4-(4-
chloro-6-(piperidin-1-yl)-1,3,5-triazine-2-ylamino)-N-(pyrimid-
in-2-yl) benzenesulfonamide. Finally the titled compounds (3a–
o) i.e. 4-(4-(aryl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-y-
lamino)-N-(pyrimidin-2-yl)benzenesulfonamides were obtained
by the reaction of intermediate (2) with different aromatic ami-
nes in 1,4-dioxane at reﬂux temperature (see Fig. 1).
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Figure 1 Structure of compounds 1 & 2.
688 N.C. Desai et al.2.2.3.1. Physical constant and characterization of 4-(4-(pheny-
lamino)-6-(piperidin-1-yl)-1,3,5-triazin-2-ylamino)-N-(pyrim-
idin-2-yl)benzenesulfonamide (3a). Yield 68%; m.p. 284–
285 C. IR (mmax, cm1, KBr): 3342 (N–H, stretching 2
amine), 2980 (Ar–C–H, stretching), 2860 (C–H, stretching, –
CH3), 1626 (C‚N, stretching), 1569 (C‚C, stretching), 1550
(N–H, bending, 2 amine), 1285 (C–N, stretching, aromatic
2 amine), 1170 (S‚O, stretching in SO2), 860 (Ar–C–H,
bending). 1H NMR (400 MHz, DMSO-d6, d, ppm): 1.54–
3.68 (m, 10H, piperidine), 6.58 (s, 2H, Ar–NH–triazine), 6.87
(t, 1H, pyrimidine), 6.93–7.62 (m, 9H, Ar–H), 8.13 (s, 1H,
pyrimidine–NH–SO2–), 8.84 (d, 2H, pyrimidine).
13C NMR
(100 MHz, DMSO-d6, d, ppm): 24.5 (1C, C4 piperidine), 25.7
(2C, C3 & C5 piperidine ring), 54.8 (2C, C2 & C6 piperidine
ring), 129.9 (1C, aromatic C–SO2NH–), 138.9 (1C, aromatic
C–NH–), 142.4 (1C, –SO2-aromatic C–NH–), 157.9 (2C, C4
& C6 pyrimidine ring), 165.7 (1C, C2 triazine ring), 168.9
(1C, C4 triazine ring), 169.3 (1C, C2 pyrimidine ring), 176.0
(1C, C6 triazine ring). LC–MS (m/z):503.19 [M
+]. Anal. Calcd.for C24H25N9O2S: C, 57.24; H, 5.00; N, 25.03; Found: C,
57.32; H, 5.05; N, 25.09%.
2.2.3.2. Physical constant and characterization of 4-(4-
((3-chlorophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-yl)
amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3b). Yield
74%; m.p. 278–279 C. IR (mmax, cm1, KBr): 3340 (N–H,
stretching, 2 amine), 2983 (Ar–C–H, stretching), 2858 (C–H,
stretching, –CH3), 1629 (C‚N, stretching), 1569 (C‚C,
stretching), 1552 (N–H, bending, 2 amine), 1281 (C–N,
stretching, aromatic 2 amine), 1175 (S‚O, stretching in
SO2), 862 (Ar–C–H, bending), 677 (C–Cl, stretching).
1H
NMR (400 MHz, DMSO-d6, d, ppm):1.57–3.69 (m, 10H,
piperidine), 6.55 (s, 2H, Ar–NH–triazine), 6.91 (t, 1H, pyrim-
idine), 7.14–7.80 (m, 8H, Ar–H), 8.15 (s, 1H, pyrimidine–
NH–SO2–), 8.87 (d, 2H, pyrimidine).
13C NMR (100 MHz,
DMSO-d6, d, ppm): 24.5 (1C, C4 piperidine), 25.4 (2C, C3 &
C5 piperidine ring), 54.7 (2C, C2 & C6 piperidine ring), 129.7
(1C, aromatic C–SO2NH–), 135.2 (1C, aromatic C3-Cl),
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NH–), 157.8 (2C, C4 & C6 pyrimidine ring), 165.7 (1C, C2 tri-
azine ring), 168.9 (1C, C4 triazine ring), 169.4 (1C, C2 pyrim-
idine ring), 176.1 (1C, C6 triazine ring). LC–MS (m/z):537.15
[M+]. Anal. Calcd. for C24H24ClN9O2S: C, 53.58; H, 4.50;
N, 23.43; Found: C, 53.48; H, 4.59; N, 23.40%.
2.2.3.3. Physical constant and characterization of 4-(4-
((4-chlorophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-yl)
amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3c). Yield
74%; m.p. 276–278 C. IR (mmax, cm1, KBr): 3343 (N–H,
stretching, 2 amine), 2980 (Ar–C–H, stretching), 2861 (C–H,
stretching, –CH3), 1622 (C‚N, stretching), 1564 (C‚C,
stretching), 1552 (N–H, bending, secondary amine), 1281 (C–
N, stretching, aromatic 2 amine), 1174 (S‚O, stretching in
SO2), 865 (Ar–C–H, bending), 684 (C–Cl, stretching).
1H
NMR (400 MHz, DMSO-d6, d, ppm):1.54–3.68 (m, 10H,
piperidine), 6.59 (s, 2H, Ar–NH–triazine), 6.87 (t, 1H, pyrim-
idine), 6.81–7.78 (m, 8H, Ar–H), 8.15 (s, 1H, pyrimidine–
NH–SO2–), 8.86 (d, 2H, pyrimidine).
13C NMR (100 MHz,
DMSO-d6, d, ppm): 24.5 (1C, C4 piperidine), 25.5 (2C, C3 &
C5 piperidine ring), 54.9 (2C, C2 & C6 piperidine ring), 127.6
(1C, aromatic C4-Cl), 129.7 (1C, aromatic C–SO2NH–),
137.0 (1C, aromatic C–NH–), 142.3 (1C, –SO2-aromatic
C–NH–), 157.8 (2C, C4 & C6 pyrimidine ring), 165.7 (1C, C2
triazine ring), 168.9 (1C, C4 triazine ring), 169.4 (1C, C2 pyrim-
idine ring), 176.0 (1C, C6 triazine ring). LC–MS (m/z):537.15
[M+]. Anal. Calcd. for C24H24ClN9O2S: C, 53.58; H, 4.50;
N, 23.43; Found: C, 53.45; H, 4.60; N, 23.41%.
2.2.3.4. Physical constant and characterization of 4-(4-
((2,6-chlorophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-
yl)amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3d). Yield
65%; m.p. 294–297 C. IR (mmax, cm1, KBr): 3345 (N–H,
stretching, 2 amine), 2985 (Ar–C–H, stretching), 2859 (C–H,
stretching, –CH3), 1628 (C‚N, stretching), 1570 (C‚C,
stretching), 1552 (N–H, bending, secondary amine), 1283 (C–
N, stretching, aromatic 2 amine), 1173 (S‚O, stretching in
SO2), 861 (Ar–C–H, bending), 692 (C–Cl, stretching).
1H
NMR (400 MHz, DMSO-d6, d, ppm):1.57–3.71 (m, 10H,
piperidine), 6.59 (s, 2H, Ar–NH–triazine), 6.88 (t, 1H, pyrim-
idine), 6.91–7.64 (m, 7H, Ar–H), 8.15 (s, 1H, pyrimidine–
NH–SO2–), 8.81 (d, 2H, pyrimidine).
13C NMR (100 MHz,
DMSO-d6, d, ppm): 24.2 (1C, C4 piperidine), 25.7 (2C, C3 &
C5 piperidine ring), 54.7 (2C, C2 & C6 piperidine ring), 120.8
(1C, aromatic C5-Cl), 129.8 (1C, aromatic C–SO2NH–),
133.3 (1C, aromatic C2-Cl), 137.8 (1C, aromatic C–NH–),
142.1 (1C, –SO2-aromatic C–NH–), 157.7 (2C, C4 & C6 pyrim-
idine ring), 165.9 (1C, C2 triazine ring), 168.7 (1C, C4 triazine
ring), 169.5 (1C, C2 pyrimidine ring), 176.2 (1C, C6 triazine
ring). LC–MS (m/z):571.11 [M+]. Anal. Calcd. for C24H23Cl2-
N9O2S: C, 50.35; H, 4.05; N, 22.02; Found: C, 50.33; H, 4.01;
N, 22.04%.
2.2.3.5. Physical constant and characterization of 4-(4-((3-
chloro-4-ﬂuorophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-
2-yl)amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3e).
Yield 71%; m.p. 257–259 C. IR (mmax, cm1, KBr): 3343
(N–H, stretching, 2 amine), 2987 (Ar–C–H, 2˚ stretching),
2855 (C–H, stretching, –CH3), 1627 (C‚N, stretching), 1573
(C‚C, stretching), 1552 (N–H, bending, 2 amine), 1280 (C–N, stretching, aromatic 2 amine), 1171 (S‚O, stretching in
SO2), 1044 (C–F, stretching), 863 (Ar–C–H, bending), 697
(C–Cl, stretching). 1H NMR (400 MHz, DMSO-d6, d, ppm):
1.53–3.72 (m, 10H, piperidine), 6.62 (s, 2H, Ar–NH–triazine),
6.85 (t, 1H, pyrimidine), 6.91–7.67 (m, 7H, Ar–H), 8.17 (s, 1H,
pyrimidine–NH–SO2–), 8.89 (d, 2H, pyrimidine).
13C NMR
(100 MHz, DMSO-d6, d, ppm): 24.4 (1C, C4 piperidine), 25.6
(2C, C3 & C5 piperidine ring), 54.9 (2C, C2 & C6 piperidine
ring), 121.6 (1C, aromatic C3-Cl), 129.6 (1C, aromatic C–SO2-
NH–), 139.2 (1C, aromatic C–NH–), 142.2 (1C, –SO2-aromat-
ic C–NH–), 148.7 (1C, aromatic C4-F), 157.9 (2C, C4 & C6
pyrimidine ring), 165.7 (1C, C2 triazine ring), 168.8 (1C, C4 tri-
azine ring), 169.6 (1C, C2 pyrimidine ring), 176.1 (1C, C6 tri-
azine ring). LC–MS (m/z):555.14 [M+]. Anal. Calcd. for
C24H23ClFN9O2S: C, 51.84; H, 4.17; N, 22.67; Found: C,
51.81; H, 4.15; N, 22.65%.
2.2.3.6. Physical constant and characterization of 4-((4-
(piperidin-1-yl-6-(o-tolylamino)-1,3,5-triazine-2-yl)amino)-N-
(pyrimidin-2-yl)benzenesulfonamide (3f). Yield 65%; m.p.
257–260 C. IR (mmax, cm1, KBr): 3342 (N–H, stretching, 2
amine), 2983 (Ar–C–H, stretching), 2851 (C–H, stretching,
–CH3), 1625 (C‚N, stretching), 1571 (C‚C, stretching),
1550 (N–H, bending, 2 amine), 1284 (C–N, stretching, aro-
matic 2 amine), 1170 (S‚O, stretching in SO2), 862 (Ar–C–
H, bending). 1H NMR (400 MHz, DMSO-d6, d, ppm): 1.51–
3.51 (m, 10H, piperidine), 3.57 (s, 3H, –CH3), 6.51 (s, 2H,
Ar–NH–triazine), 6.84 (t, 1H, 13C NMR (100 MHz, DMSO-
d6, d, ppm): 17.8 (1C, –CH3), 24.6 (1C, C4 piperidine), 25.4
(2C, C3 & C5 piperidine ring), 54.6 (2C, C2 & C6 piperidine
ring), 129.0 (1C, aromatic C2-CH3), 129.9 (1C, aromatic
C–SO2NH–), 142.0 (1C, aromatic C–NH–), 142.5 (1C, –SO2-
aromatic C–NH–), 157.6 (2C, C4 & C6 pyrimidine ring), 165.5
(1C, C2 triazine ring), 168.7 (1C, C4 triazine ring), 169.2 (1C,
C2 pyrimidine ring), 176.4 (1C, C6 triazine ring). LC–MS
(m/z):517.20 [M+]. Anal. Calcd. for C25H27N9O2S: C, 58.01;
H, 5.26; N, 24.35; Found: C, 58.02; H, 5.24; N, 24.33%.2.2.3.7. Physical constant and characterization of 4-((4-
(piperidin-1-yl-6-(p-tolylamino)-1,3,5-triazine-2-yl)amino)-N-
(pyrimidin-2-yl)benzenesulfonamide (3g). Yield 74%; m.p.
275–278 C. IR (mmax, cm1, KBr): 3340 (N–H, stretching, 2
amine), 2982 (Ar–C–H, stretching), 2857 (C–H, stretching, –
CH3), 1629 (C‚N, stretching), 1570 (C‚C, stretching), 1557
(N–H, bending, 2 amine), 1282 (C–N, stretching, aromatic
2 amine), 1176 (S‚O, stretching in SO2), 867 (Ar–C–H,
bending). 1H NMR (400 MHz, DMSO-d6, d, ppm): 1.52–
3.47 (m, 10H, piperidine), 3.57 (s, 3H, –CH3), 6.53 (s, 2H,
Ar–NH–triazine), 6.84 (t, 1H, pyrimidine), 6.90–7.61 (m, 8H,
Ar–H), 8.11 (s, 1H, pyrimidine–NH–SO2–), 8.82 (d, 2H,
pyrimidine). 13C NMR (100 MHz, DMSO-d6, d, ppm): 21.4
(1C, –CH3), 24.4 (1C, C4 piperidine), 25.7 (2C, C3 & C5 piper-
idine ring), 54.8 (2C, C2 & C6 piperidine ring), 129.9 (1C, aro-
matic C–SO2NH–), 131.3 (1C, aromatic C4-CH3), 135.8 (1C,
aromatic C–NH–), 142.2 (1C, –SO2-aromatic C–NH–), 157.8
(2C, C4 & C6 pyrimidine ring), 165.8 (1C, C2 triazine ring),
168.8 (1C, C4 triazine ring), 169.4 (1C, C2 pyrimidine ring),
176.1 (1C, C6 triazine ring). LC–MS (m/z):517.20 [M
+]. Anal.
Calcd. for C25H27N9O2S: C, 58.01; H, 5.26; N, 24.35; Found:
C, 58.03; H, 5.21; N, 24.36%.
690 N.C. Desai et al.2.2.3.8. Physical constant and characterization of 4-((2,4-
dimethylphenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-yl)
amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3h). Yield
72%; m.p. 248–249 C. IR (mmax, cm1, KBr): 3342 (N–H,
stretching, 2 amine), 2989 (Ar–C–H, stretching), 2853 (C–H,
stretching, –CH3), 1625 (C‚N, stretching), 1577 (C‚C,
stretching), 1553 (N–H, bending, 2 amine), 1287 (C–N,
stretching, aromatic 2 amine), 1173 (S‚O, stretching in
SO2), 862 (Ar–C–H, bending), 679 (C–Cl, stretching).
1H
NMR (400 MHz, DMSO-d6, d, ppm): 1.53–3.48 (m, 10H,
piperidine), 3.52 (s, 6H, –CH3), 6.55 (s, 2H, Ar–NH–triazine),
6.85 (t, 1H, pyrimidine), 6.91–7.63 (m, 7H, Ar–H), 8.10 (s, 1H,
pyrimidine–NH–SO2–), 8.82 (d, 2H, pyrimidine).
13C NMR
(100 MHz, DMSO-d6, d, ppm): 17.8 (1C, 2-CH3), 21.7 (1C,
4-CH3), 24.6 (1C, C4 piperidine), 25.6 (2C, C3 & C5 piperidine
ring), 54.5 (2C, C2 & C6 piperidine ring), 128.8 (1C, aromatic
C2-CH3), 129.6 (1C, aromatic C–SO2NH–), 137.8 (1C, aromat-
ic C4-CH3), 139.2 (1C, aromatic C–NH–), 142.4 (1C, –SO2-
aromatic C–NH–), 157.6 (2C, C4 & C6 pyrimidine ring),
165.6 (1C, C2 triazine ring), 168.7 (1C, C4 triazine ring),
169.2 (1C, C2 pyrimidine ring), 176.2 (1C, C6 triazine ring).
LC–MS (m/z):531.22 [M+]. Anal. Calcd. for C26H29N9O2S:
C, 58.74; H, 5.50; N, 23.71; Found: C, 58.75; H, 5.48; N,
23.69%.
2.2.3.9. Physical constant and characterization of 4-((3-chloro-
2-methylphenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-
yl)amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3i). Yield
75%; m.p. 264–267 C. IR (mmax, cm1, KBr): 3345 (N–H,
stretching, 2 amine), 2985 (Ar–C–H, stretching), 2851 (C–H,
stretching, –CH3), 1622 (C‚N, stretching), 1579 (C‚C,
stretching), 1554 (N–H, bending, 2 amine), 1287 (C–N,
stretching, aromatic 2 amine), 1179 (S‚O, stretching in
SO2), 868 (Ar–C–H, bending).
1H NMR (400 MHz, DMSO-
d6, d, ppm):1.53–3.47 (m, 10H, piperidine), 3.54 (s, 3H,
–CH3), 6.55 (s, 2H, Ar–NH–triazine), 6.84 (t, 1H, pyrimidine),
6.91–7.60 (m, 7H, Ar–H), 8.15 (s, 1H, pyrimidine–NH–SO2–),
8.87 (d, 2H, pyrimidine). 13C NMR (100 MHz, DMSO-d6, d,
ppm): 14.4 (1C, 2-CH3), 24.4 (1C, C4 piperidine), 25.7 (2C,
C3 & C5 piperidine ring), 54.7 (2C, C2 & C6 piperidine ring),
129.6 (1C, aromatic C–SO2NH–), 130.2 (1C, aromatic
C2-CH3), 133.4 (1C, aromatic C3-Cl), 142.4 (1C, –SO2-aromat-
ic C–NH–), 143.5 (1C, aromatic C–NH–), 157.8 (2C, C4 & C6
pyrimidine ring), 165.8 (1C, C2 triazine ring), 168.8 (1C, C4
triazine ring), 169.4 (1C, C2 pyrimidine ring), 176.1 (1C, C6
triazine ring). LC–MS (m/z):551.16 [M+]. Anal. Calcd. for
C25H26ClN9O2S: C, 54.39; H, 4.75; N, 22.83; Found: C,
54.37; H, 4.72; N, 22.81%.
2.2.3.10. Physical constant and characterization of 4-((4-
(piperidin-1-yl)-6-((4-(triﬂuoromethyl)phenyl)amino)-1,3,5-
triazine-2-yl)amino)-N-(pyrimidin-2-yl)benzenesulfonamide
(3j). Yield 70%; m.p. 273–275 C. IR (mmax, cm1, KBr): 3342
(N–H, stretching, 2 amine), 2984 (Ar–C–H, stretching), 2858
(C–H, stretching, –CH3), 1624 (C‚N, stretching), 1572
(C‚C, stretching), 1558 (N–H, bending, 2 amine), 1282 (C–
N, stretching, aromatic 2 amine), 1173 (S‚O, stretching in
SO2), 1059 (C–F, stretching), 862 (Ar–C–H, bending).
1H
NMR (400 MHz, DMSO-d6, d, ppm): 1.55–3.51 (m, 10H,
piperidine), 6.57 (s, 2H, Ar–NH–triazine), 6.89 (t, 1H, pyrim-
idine), 6.96–7.65 (m, 8H, Ar–H), 8.14 (s, 1H, pyrimidine–NH–SO2–), 8.87 (d, 2H, pyrimidine).
13C NMR (100 MHz,
DMSO-d6, d, ppm): 24.7 (1C, C4 piperidine), 25.6 (2C, C3 &
C5 piperidine ring), 54.9 (2C, C2 & C6 piperidine ring),
124.2, (1C, CF3), 126.6 (1C, aromatic C4-CF3), 129.6 (1C, aro-
matic C–SO2NH–), 142.2 (1C, –SO2-aromatic C–NH–), 142.7
(1C, aromatic C–NH–), 157.7 (2C, C4 & C6 pyrimidine ring),
165.6 (1C, C2 triazine ring), 168.7 (1C, C4 triazine ring),
169.6 (1C, C2 pyrimidine ring), 176.3 (1C, C6 triazine ring).
LC–MS (m/z): 571.17 [M+]. Anal. Calcd. for C25H24F3N9O2-
S: C, 52.53; H, 4.23; N, 22.05; Found: C, 52.51; H, 4.22; N,
22.03%.2.2.3.11. Physical constant and characterization of 4-((4-((4-
methoxyphenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-yl)
amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3k). Yield
76%; m.p. 277–280 C. IR (mmax, cm1, KBr): 3348 (N–H,
stretching, 2 amine), 2981 (Ar–C–H, stretching), 2852 (C–H,
stretching, –CH3), 2832 (C–H, stretching in C-O-CH3), 1628
(C‚N, stretching), 1575 (C‚C, stretching), 1552 (N–H, bend-
ing, 2 amine), 1280 (C–N, stretching, aromatic 2 amine),
1177 (S‚O, stretching in SO2), 860 (Ar–C–H, bending).
1H
NMR (400 MHz, DMSO-d6, d, ppm): 1.55–3.51 (m, 10H,
piperidine), 3.58 (s, 3H, –OCH3), 6.61 (s, 2H, Ar–NH–tri-
azine), 6.89 (t, 1H, pyrimidine), 6.95–7.64 (m, 8H, Ar–H),
8.17 (s, 1H, pyrimidine–NH–SO2), 8.88 (d, 2H, pyrimidine).
13C NMR (100 MHz, DMSO-d6, d, ppm): 24.3 (1C, C4 piper-
idine), 25.4 (2C, C3 & C5 piperidine ring), 54.6 (2C, C2 & C6
piperidine ring), 55.7 (1C, OCH3), 129.5 (1C, aromatic C–SO2-
NH–), 131.3 (1C, aromatic C–NH–), 142.1 (1C, –SO2-aromat-
ic C–NH–), 153.4 (1C, aromatic C-OCH3), 157.4 (2C, C4 & C6
pyrimidine ring), 165.9 (1C, C2 triazine ring), 168.8 (1C, C4 tri-
azine ring), 169.2 (1C, C2 pyrimidine ring), 176.1 (1C, C6 tri-
azine ring). LC–MS (m/z):533.20 [M+]. Anal. Calcd. for
C25H27N9O2S: C, 56.27; H, 5.10; N, 23.62; Found: C, 56.25;
H, 5.11; N, 23.61%.2.2.3.12. Physical constant and characterization of 4-((4-((2,5-
dimethoxyphenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-
yl)amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3l). Yield
79%; m.p. 287–289 C. IR (mmax, cm1, KBr): 3341 (N–H,
stretching, 2 amine), 2985 (Ar–C–H, stretching), 2850 (C–H,
stretching, –CH3), 2831 (C–H, stretching in C-O–CH3), 1625
(C‚N, stretching), 1572 (C‚C, stretching), 1550 (N–H, bend-
ing, 2 amine), 1282 (C–N, stretching, aromatic 2 amine),
1179 (S‚O, stretching in SO2), 865 (Ar–C–H, bending).
1H
NMR (400 MHz, DMSO-d6, d, ppm): 1.55–3.54 (m, 10H,
piperidine), 3.65 (s, 6H, –OCH3), 6.62 (s, 2H, Ar–NH–tri-
azine), 6.90 (t, 1H, pyrimidine), 6.94–7.67 (m, 7H, Ar–H),
8.14 (s, 1H, pyrimidine–NH–SO2–), 8.87 (d, 2H, pyrimidine).
13C NMR (100 MHz, DMSO-d6, d, ppm): 24.5 (1C, C4 piper-
idine), 25.5 (2C, C3 & C5 piperidine ring), 54.5 (2C, C2 &
C6 piperidine ring), 55.8 (2C, OCH3), 129.5 (1C, aromatic
C–SO2NH–), 133.7 (1C, aromatic C–NH–), 139.8 (1C, aro-
matic C2-OCH3), 142.3 (1C, –SO2-aromatic C–NH–), 153.7
(1C, aromatic C5-OCH3), 157.6 (2C, C4 & C6 pyrimidine ring),
165.6 (1C, C2 triazine ring), 168.6 (1C, C4 triazine ring), 169.4
(1C, C2 pyrimidine ring), 176.3 (1C, C6 triazine ring). LC–MS
(m/z):563.21 [M+]. Anal. Calcd. for C26H29N9O4S: C, 55.40;
H, 5.19; N, 27.37; Found: C, 55.41; H, 5.17; N, 27.35%.
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ethoxyphenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-yl)a-
mino)-N-(pyrimidin-2-yl)benzenesulfonamide (3m). Yield
64%; m.p. 299–300 C. IR (mmax, cm1, KBr): 3348 (N–H,
stretching, 2 amine), 2982 (Ar–C–H, stretching), 2833 (C–H,
stretching in C–O–C2H5), 1625 (C‚N, stretching), 1572
(C‚C, stretching), 1554 (N–H, bending, 2 amine), 12,881
(C–N, stretching, aromatic 2 amine), 1171 (S‚O, stretching
in SO2), 867 (Ar–C–H, bending).
1H NMR (400 MHz,
DMSO-d6, d, ppm):1.35 (t, 3H, OCH2CH3), 1.56–3.67 (m,
10H, piperidine), 3.95 (q, 2H, OCH2CH3), 6.59 (s, 2H, Ar–
NH–triazine), 6.88 (t, 1H, pyrimidine), 6.95–7.67 (m, 8H,
Ar–H), 8.18 (s, 1H, pyrimidine–NH–SO2–), 8.87 (d, 2H,
pyrimidine). 13C NMR (100 MHz, DMSO-d6, d, ppm): 24.4
(1C, C4 piperidine), 25.7 (2C, C3 & C5 piperidine ring), 54.6
(2C, C2 & C6 piperidine ring), 64.8 (1C, OCH3), 129.6 (1C,
aromatic C–SO2NH–), 130.7 (1C, aromatic C–NH–), 142.1
(1C, –SO2-aromatic C–NH–), 152.1 (1C, aromatic
C4-OCH3), 157.7 (2C, C4 & C6 pyrimidine ring), 165.5 (1C,
C2 triazine ring), 168.7 (1C, C4 triazine ring), 169.3 (1C, C2
pyrimidine ring), 176.0 (1C, C6 triazine ring). LC–MS (m/
z):547.21 [M+]. Anal. Calcd. for C26H29N9O3S: C, 57.02; H,
5.34; N, 23.02; Found: C, 57.01; H, 5.31; N, 23.03%.2.2.3.14. Physical constant and characterization of 4-((4-
((4-nitrophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazine-2-yl)
amino)-N-(pyrimidin-2-yl)benzenesulfonamide (3n). Yield
62%; m.p. 275–277 C. IR (mmax, cm1, KBr): 3344 (N–H,
stretching, 2 amine), 2980 (Ar–C–H, stretching), 1627
(C‚N, stretching), 1579 (C‚C, stretching), 1582 (C–NO2,
stretching), 1550 (N–H, bending, 2 amine), 1285 (C–N,
stretching, aromatic 2 amine), 1172 (S‚O, stretching in
SO2), 866 (Ar–C–H, bending).
1H NMR (400 MHz, DMSO-
d6, d, ppm): 1.52–3.61 (m, 10H, piperidine), 6.55 (s, 2H, Ar–
NH–triazine), 6.86 (t, 1H, pyrimidine), 6.91–7.58 (m, 8H,
Ar–H), 8.11 (s, 1H, pyrimidine–NH–SO2–), 8.82 (d, 2H,
pyrimidine). 13C NMR (100 MHz, DMSO-d6, d, ppm): 24.7
(1C, C4 piperidine), 25.6 (2C, C3 & C5 piperidine ring), 54.5
(2C, C2 & C6 piperidine ring), 129.5 (1C, aromatic C–SO2
NH–), 137.2 (1C, aromatic C4-NO2), 142.3 (1C, –SO2-aromat-
ic C–NH–), 145.2 (1C, aromatic C–NH–), 157.5 (2C, C4 & C6
pyrimidine ring), 165.6 (1C, C2 triazine ring), 168.6 (1C, C4
triazine ring), 169.2 (1C, C2 pyrimidine ring), 176.1 (1C, C6
triazine ring). LC–MS (m/z):548.17 [M+]. Anal. Calcd. for
C24H24N10O4S: C, 52.55; H, 4.41; N, 25.53; Found: C, 52.53;
H, 4.40; N, 25.51%.2.2.3.15. Physical constant and characterization of ethyl-4-
((4-piperidin-1-yl)-6-((4-(N-(pyrimidin-2-yl)sulfamoyl)phenyl)
amino)-1,3,5-triazine-2-yl)amino)benzoate (3o). Yield 65%;
m.p. 278–280 C. IR (mmax, cm1, KBr): 3346 (N–H, stretching,
2 amine), 2981 (Ar–C–H, stretching), 1742 (C‚O, stretching,
ester), 1625 (C‚N, stretching), 1575 (C‚C, stretching), 1552
(NH, bending, 2 amine), 1283 (C–N, stretching, aromatic 2
amine), 1177 (S‚O, stretching in SO2), 869 (Ar–C–H, bend-
ing). 1H NMR (400 MHz, DMSO-d6, d, ppm): 1.31 (t, 3H, –
COOCH2CH3), 1.55–3.71 (m, 10H, piperidine), 4.12 (q, 2H,
–COOCH2CH3), 6.61 (s, 2H, Ar–NH–triazine), 6.89 (t, 1H,
pyrimidine), 6.95–7.65 (m, 8H, Ar–H), 8.17 (s, 1H, pyrim-
idine–NH–SO2–), 8.89 (d, 2H, pyrimidine).
13C NMR(100 MHz, DMSO-d6, d, ppm): 14.2 (1C, CH3 of –COOCH2-
CH3), 24.5 (1C, C4 piperidine), 25.5 (2C, C3 & C5 piperidine
ring), 54.6 (2C, C2 & C6 piperidine ring), 60.7 (1C, CH2 of –
COOCH2CH3), 129.5 (1C, aromatic C–SO2NH–), 142.1 (1C,
–SO2-aromatic C–NH–), 143.4 (1C, aromatic C–NH–), 157.6
(2C, C4 & C6 pyrimidine ring), 165.2 (1C, C2 triazine ring),
165.9 (1C, CO of –COOCH2CH3), 168.7 (1C, C4 triazine ring),
169.1 (1C, C2 pyrimidine ring), 176.2 (1C, C6 triazine ring).
LC–MS (m/z):575.21 [M+]. Anal. Calcd. for C27H29N9O4S:
C, 56.34; H, 5.08; N, 21.90; Found: C, 56.33; H, 5.06; N,
21.92%.
3. Antibacterial assay
The antibacterial assay of synthesized compounds was carried
out by preparing serial dilution of given solution using the
Mueller Hinton Broth dilution method (Becton Dickinson,
USA) [27], Desai [28–29]. The standard strains used for antimi-
crobial activity were procured from the Institute of Microbial
Technology, Chandigarh. The compounds (3a–o) were
screened for their antibacterial activity in triplicate sets against
these bacteria at different concentrations of 1000, 500, 250 and
200 lg/mL. The drugs which were found to be active in prima-
ry screening were further diluted to obtain 100, 50 and 25 lg/
mL concentrations. 10 lg/mL suspensions were further
inoculated on appropriate media and growth was noted after
24 and 48 h. The lowest concentration, which showed no
growth after spot subculture was considered as MIC for each
drug. The highest dilution showing at least 99% inhibition
was taken as minimum inhibitory concentration (MIC). The
test mixture should contain 108 cells/mL. The standard drug
used in this study was ampicillin for evaluating antibacterial
activity which showed (100, 100, 250 and 100 lg/mL) MIC
against Escherichia coli, Pseudomonas aeruginosa, Staphylococ-
cus aureus and Staphylococcus pyogenes respectively.
4. Antifungal assay
Compounds (3a–o) were tested for antifungal activity in trip-
licate sets against Candida albicans, Aspergillus niger and
Aspergillus clavatus at various concentrations of 1000, 500,
250, 200 and 100 lg/mL and the obtained results were
recorded in the form of primary and secondary screening.
The compounds which were found to be active in this prima-
ry screening were further tested in a second set of dilution
against all microorganisms. The lowest concentration, which
showed no growth after spot subculture was considered as
MIC for each drug. The highest dilution showing at least
99% inhibition was taken as MIC. The test mixture should
contain 108 spores/mL MIC. Griseofulvin was used as a stan-
dard drug for antifungal activity, which showed (500, 100 and
100 lg/mL) MIC against C. albicans, A. niger and A. clavatus
respectively.
5. Antimicrobial activity
The synthesized compounds were evaluated against Gram-posi-
tive bacteria [S. aureus (MTCC 96), S. pyogenes (MTCC 442)],
Gram-negative bacteria [E. coli (MTCC 443), P. aeruginosa
(MTCC 1688)] and fungal strains [C. albicans (MTCC 227), A.
niger (MTCC 282), A. clavatus (MTCC 1323)]. The individual
Table 1 Results of biological activities of compounds (3a–o).
Sr. No. –R Minimum inhibitory concentration (MIC) in lg/mL Minimum inhibitory concentration (MIC) in lg/mL
E. coli
MTCC 443
P. aeruginosa
MTCC 1688
S. aureus
MTCC 96
S. pyogenes
MTCC 442
C. albicans
MTCC 227
A. niger
MTCC 282
A. clavatus
MTCC 1323
3a –H 200 100 100 50 >1000 >1000 >1000
3b –3-Cl 100 50 100 200 250 500 >1000
3c –4-Cl 25 100 200 100 500 >1000 >1000
3d –2,6-(Cl)2 100 50 200 100 500 >1000 >1000
3e –3-Cl–4-F 50 100 100 500 500 500 >1000
3f –2-CH3 200 250 200 1000 250 250 >1000
3g –4-CH3 250 250 250 250 250 500 1000
3h –2,4-(CH3)2 250 250 250 1000 500 1000 >1000
3i –3-Cl-2-CH3 200 100 500 1000 250 500 >1000
3j –4-CF3 100 250 500 100 >1000 500 >1000
3k –4-OCH3 100 250 250 500 >1000 >1000 >1000
3l –2,5-(OCH3)2 200 250 500 250 >1000 >1000 >1000
3m –4-OC2H5 100 500 100 100 500 1000 1000
3n –4-NO2 25 50 100 100 1000 >1000 >1000
3o –4-COOC2H5 25 25 100 100 1000 >1000 >1000
Ampicillin 100 100 250 100 – – –
Griseofulvin – – – – 500 100 100
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ed compounds (3a–o) against the test microbes are listed in
Table 1 along with the MIC values of reference compounds
ampicillin (for bacteria) and griseofulvin (for fungi). The results
revealed that majority of synthesized compounds exhibited
varying degrees of inhibition against the tested panel of species.
The antimicrobial activity of tested compounds can be correlat-
ed to structural variations and modiﬁcations of the respective
compounds. From antimicrobial activity data (Table 1), it was
observed that compounds 3c (–4-Cl), 3n (–4-NO2) and 3o (–4-
COOC2H5) showed excellent activity against E. coli at MIC
25 lg/mL. Compound 3e (–3-Cl, –4-F) demonstrated very good
activity against E.coli at MIC 50 lg/mL. Compounds 3b (–3-
Cl), 3d (–2,6-(Cl)2), 3j (–4-CF3), 3k (–4-OCH3) and 3m (–4-
OC2H5) exhibited good activity against E. coli at MIC 100 lg/
mL. Among the synthesized compounds, 3o (–4-COOC2H5)
was found to be most potent compared to standard drug at
MIC 25 lg/mL against P. aeruginosa. Compounds 3b (–3-Cl),
3d (–2,6-(Cl)2) and 3n (–4-NO2) exhibited very good activity
against P. aeruginosa at MIC 50 lg/mL, while compounds 3a
(–H), 3c (–4-Cl), 3e (3-Cl, –4-F) and 3i (–3-Cl, –2CH3) furnished
good activity against P. aeruginosa at MIC 100 lg/mL. Com-
pounds 3a (–H), 3b (–3-Cl), 3e (–3-Cl, –4-F), 3m (–4-OC2H5),
3n (–4-NO2) and 3o (–4-COOC2H5) showed very good activity
against S. aureus at MIC 100 lg/mL. Compounds 3c (–4-Cl),
3d (–2,6-(Cl)2) and 3f (–2-CH3) displayed good activity against
S. aureus at MIC 200 lg/mL and compounds 3g (–4-CH3), 3h
(–2,4-(CH3)2) and 3k (–4-OCH3) exhibited moderate activity
against S. aureus at MIC 250 lg/mL. Compounds 3a (–H) pos-
sessed highest inhibition against S. pyogenes at MIC 50 lg/mL
and compounds 3c (–4-Cl), 3d (–2,6-(Cl)2), 3j (–4-CF3), 3m (–
4-OC2H5), 3n (–4-NO2) and 3o (–4-COOC2H5) demonstrated
good activity against S. pyogenes at MIC 100 lg/mL. Com-
pounds 3b (–3-Cl), 3f (–2-CH3), 3g (–4-CH3) and 3i (–3-Cl, –2-
CH3) revealed very good activity against C. albicans at MIC
250 lg/mL and compounds 3c (–4-Cl), 3d (–2,6-(Cl)2), 3e (–3-
Cl, –4-F), 3h (–2,4-(CH3)2) and 3m (–4-OC2H5) furnished mod-
erate activity against C. albicans at MIC 500 lg/mL.6. Result and discussion
The characterization of newly synthesized compounds of the
series (3a–o) was accomplished by IR, 1H NMR,13C NMR
and Mass spectral analysis. Titled compound (3a) possesses
three motif benzenesulfonamide, piperidine and 1,3,5-triazine.
From IR spectra, 2 amines (i.e. –NH–) directly attached to
the triazine ring indicated strong absorption band at
3342 cm1. The absorption due to C‚N stretching in pyrim-
idine and s-triazine rings appeared at 1626 cm1. The presence
of C–N stretching in pyrimidine, triazine and piperidine rings
was demonstrated by intense absorption at 1285 cm1. Due
to S‚O stretching in benzenesulfonamide, a medium intensity
absorption band was observed at 1170 cm1. In 1H NMR spec-
tra of the title compound (3a), two Ar–NH–triazine protons
appeared as a singlet at d= 6.58 ppm whereas one proton of
–NH–SO2– was observed as a singlet at d= 8.13 ppm. Nine
protons of phenyl rings indicated a multiplet between
d= 6.93 and 7.62 ppm. A multiplet signal between d= 1.54
and 3.68 ppm demonstrated the presence of ten protons in
the piperidine ring. NMR signals for protons of the pyrimidine
ring appeared as a doublet at d= 8.45 ppm and a triplet at
d= 6.87 ppm. On the basis of 13C NMR of the ﬁnal compound
(3a), the chemical shift varied between d= 24.5 and
176.0 ppm. Carbons of piperidine showed a chemical shift at
d= 24.5–54.8 ppm. Three carbons of 1,3,5-triazine nucleus
directly bonded to nitrogen atoms exhibited NMR signals at
d= 117.9, 168.9 and 176.0 ppm. Carbons of pyrimidine moiety
appeared at d= 115.3–169.3 ppm. The twelve carbons of aro-
matic rings were observed between d= 113.7 and 138.9 ppm.
7. Structure activity relationship (SAR)
The substitution pattern of s-triazine derivatives was carefully
selected to confer different electronic environments to the
molecules. The results from antimicrobial activity suggested
that s-triazine derivatives were remarkably inﬂuenced by var-
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compounds of this series exhibited signiﬁcant antibacterial
and moderate antifungal activities. The bioassay results
demonstrated that some analogs were very active at MIC val-
ues 25–50 lg/mL. Among the synthesized compounds, 3c (–4-
Cl), 3n (–4-NO2) and 3o (-COOC2H5) exhibited highest inhibi-
tion against bacterial strains E. coli at MIC 25 lg/mL. Fur-
thermore, compound 3n showed signiﬁcant inhibition against
P. aeruginosa at MIC 25 lg/mL and compound 3o exhibited
signiﬁcant activity against P. aeruginosa at MIC 25 lg/mL.
The data revealed that replacement of hydrogen on the phenyl
ring of the targeted compound (3a) from para position with
electron withdrawing groups like halogen, nitro and ester
remarkably enhanced the antimicrobial activity against select-
ed microorganisms. Thus, our aim was to explore SAR of syn-
thesized compounds and to develop lead molecules for further
optimization.
8. Conclusion
The interest of organic chemists in 2,4,6-trichloro-1,3,5-tri-
azine as a starting material is due to the temperature depen-
dent reactivity of three chlorine atoms that allow a
sequential introduction of various substituents. In the present
article, we have reported the synthesis, characterization and
antimicrobial activity of some novel s-triazine based piperidine
and benzenesulfonamide derivatives. Out of the ﬁfteen com-
pounds, 3c, 3n and 3o exhibited signiﬁcant antimicrobial activ-
ity on several strains of microbes. It is worth mentioning that
insertion of various electron withdrawing groups enhanced the
pharmacological activities of the resultant scaffolds by lower-
ing the MIC values. It may be concluded that electron with-
drawing substituents on the phenyl ring are most suitable for
the present scaffold to achieve optimum antimicrobial spec-
trum. In short, the present study can lead medicinal chemists
to design and synthesize similar compounds with enhanced
biological potency in future.
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